Kohjin Bio Co (177A.T) Stock Price

Kohjin Bio Co Price

CLOSED
815.00
​
Market closed

Over the last 3 years Kohjin Bio Co grew revenue by 9.7% annually, reaching 5.21 B JPY. Earnings per share have grown at 10.4% per year over the last 3 years. For Kohjin Bio Co, the net margin of 15.3% is broadly stable versus 14.9% a few years ago. At today's price the dividend yield works out to roughly 2.94%. The payout ratio is around 15% of earnings.

Kohjin Bio Co stock price

Access this data via the Eulerpool API

Kohjin Bio Co business model & stock analysis

Kohjin Bio Co Ltd is a JP-based company operating in industry. The company is headquartered in Sakado-Shi, Saitama-Ken and currently employs 139 full-time employees. The company went IPO on 2024-04-25. Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The firm operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.

Frequently asked questions about Kohjin Bio Co

Converted at the current exchange rate, the Kohjin Bio Co share trades at 4.60 EUR (815.00 JPY).

The expected revenue of Kohjin Bio Co is 5.13 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Kohjin Bio Co is 683.21 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Kohjin Bio Co is currently 6.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kohjin Bio Co stock.

The price-to-sales ratio (P/S) of Kohjin Bio Co is currently 0.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kohjin Bio Co stock.

The Eulerpool Quality Score for Kohjin Bio Co is 2/10.

The ISIN of Kohjin Bio Co is JP3283630006. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Kohjin Bio Co is 177A.T. The ticker symbol is used to trade Kohjin Bio Co shares on the stock exchange.

Fair ValueTerminal
790.55 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue per Employee
37.46 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Apr 25, 2024
ISIN
JP3283630006
Cusip
J3478W106
Market capitalization
4.16 B JPYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
6.10
P/Ee 2027
—
P/S
P/Se
0.80
EV/EBIT
3.43
P/B Ratio
0.72
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
9.73 %
Dividend
Dividend yield
2.94 %
Est. Dividend Yield
4.17 %
Payout Ratio
15.23 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
1 year
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
15.32 %
Last updated Oct 10, 2026, 8:05 PM

Kohjin Bio Co Peer Group

All fundamentals and in-depth analysis of Kohjin Bio Co

Our stock analysis for Kohjin Bio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kohjin Bio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.